Search Results
Oct 15, 2025, 10:40 ET Commercial Distributed Energy Generation Market Size Worth USD 367.8 Billion by 2033, Growing at 11.0% CAGR from 2026-2033 : - Market Research Intellect
Global Checkpoint Inhibitors For Treating Cancer Market Size By Application (Lung Cancer, Melanoma, Bladder Cancer, Hodgkin Lymphoma, Head and Neck Cancers), By Product (PD-1 Inhibitors (Programmed Cell Death Protein 1), PD-L1 Inhibitors
More news about: Market Research Intellect
Oct 15, 2025, 10:02 ET TVRD SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company
More news about: Faruqi & Faruqi, LLP
Oct 15, 2025, 10:00 ET Metastatic Brain Tumor Collaborative Announces First-Ever Collaborative Grant Opportunity Focused on CNS Metastasis
CNS metastases are the most common type of brain tumor in adults, occurring when cancers such as breast, lung, melanoma, colorectal, and kidney spread to the brain or spinal cord. Despite affecting more than 200,000 people in the U.S. each year, this patient
More news about: American Brain Tumor Association
Oct 15, 2025, 09:11 ET Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
candidate moving toward the clinic. GTB-5550 targets a protein called B7H3 that appears in many different types of solid tumors, including breast, lung, ovarian, head and neck, pancreatic, bladder, and prostate cancers. The company expects to
More news about: USA News Group
Oct 15, 2025, 09:00 ET GC Biopharma Announces Symposium on Clinical and Patient Experience in Primary Immunodeficiency and Poster Presentations on IVIG Manufacturing and Viscosity at the 2025 IgNS Annual Meeting
particularly patients with risk factors. Transfusion-Related Acute Lung Injury: Noncardiogenic pulmonary edema (transfusion-related acute lung injury [TRALI]) may occur. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal
More news about: GC Biopharma USA Inc.
Oct 15, 2025, 08:45 ET Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
therapies that previously required lengthy hospital stays[4]. Alternative drug delivery methods and targeted therapy approvals for lung cancer, breast cancer, and multiple myeloma demonstrate how precision oncology tools are accelerating patient access to breakthrough treatments[1].
More news about: Equity Insider
Oct 15, 2025, 08:00 ET OncoHost to Present New Research on Plasma Proteomics-Based Treatment Selection in Melanoma at ESMO 2025
decisions for metastatic melanoma," explores the potential of the company's PROphet® model—originally developed and validated in non-small cell lung cancer (NSCLC)—to inform treatment selection in melanoma, a setting where biomarkers to guide clinical decisions remain limited.
More news about: OncoHost
Oct 15, 2025, 08:00 ET Ouro Medicines Announces Expansion of Clinical Development for OM336 in Sjögren's Disease and Idiopathic Inflammatory Myopathy
systems beyond muscle, including the lungs, heart, skin and joints, with many patients developing life-threatening complications such as interstitial lung disease. Autoantibody-driven manifestations can significantly impact quality of life and long-term outcomes. Current treatment approaches
More news about: Ouro Medicines
Oct 15, 2025, 07:00 ET Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025
greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two therapies approved to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering,
More news about: Insmed Incorporated
Oct 15, 2025, 07:00 ET CAPS Medical's PlasmaSure™ Receives FDA Breakthrough Device Designation
Indications Building on its clinical success in NMIBC, CAPS Medical is advancing pre-clinical programs in lung, esophageal, gastric, and prostate cancer, among others. Early data from these studies show promising tumor ablation results, reinforcing the potential
More news about: CAPS Medical
Oct 15, 2025, 06:30 ET Wellcare Enhances Offering of Affordable, Quality Medicare Advantage and Medicare Prescription Drug Plans in 2026
must have one or more of the following chronic conditions: cancer, cardiovascular disorders, chronic and disabling mental health conditions, chronic lung disorders, diabetes. There are other eligible conditions not listed. Eligibility for this benefit cannot be guaranteed based solely on your condition.
More news about: Centene Corporation
Oct 15, 2025, 06:00 ET Wellcare Enhances Offering of Affordable, Quality Medicare Advantage and Medicare Prescription Drug Plans in 2026
must have one or more of the following chronic conditions: cancer, cardiovascular disorders, chronic and disabling mental health conditions, chronic lung disorders, diabetes. There are other eligible conditions not listed. Eligibility for this benefit cannot be guaranteed based solely on your condition.
More news about: Wellcare
Oct 15, 2025, 03:00 ET Aignostics Launches AI-Powered Application for Tumor Microenvironment Profiling
for refined cell niche analyses. The application will initially be made available to biopharma partners for breast, bladder, colorectal, liver, and lung cancer. Academic access will be introduced in the coming months, along with additional cancer types and analyses. Organizations interested in a free
More news about: Aignostics
Oct 15, 2025, 03:00 ET Aignostics Launches AI-Powered Application for Tumor Microenvironment Profiling
for refined cell niche analyses. The application will initially be made available to biopharma partners for breast, bladder, colorectal, liver, and lung cancer. Academic access will be introduced in the coming months, along with additional cancer types and analyses. Organizations interested in a free
More news about: Aignostics
Oct 14, 2025, 13:05 ET Policy Gaps and Health Plan Barriers Are Failing COPD Patients
Americans living with COPD can expect medical costs to be over $4,000 per year. This year, the World Health Organization adopted the Lung Health Resolution to address chronic respiratory diseases, including COPD. The resolution elevated COPD as a global health priority, but more action
More news about: COPD Action Alliance
Oct 14, 2025, 12:29 ET Smart Snacking Part of a Healthy Diet
heart disease.5 Reduced cancer risk: Including colorectal, gastric, pancreatic and lung cancers.6 Weight management: A considerable amount of evidence shows incorporating
More news about: The Peanut Institute
Oct 14, 2025, 12:00 ET Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress
response rate (ORR) of 42.9% and a disease control rate (DCR) of 100%. Among lung cancer patients treated at the 4.0 mg/kg Q2W and reaching tumor assessment, the ORR for small cell lung cancer (SCLC) and squamous non-small cell lung cancer (Sq-NSCLC) were 50.0% and 38.5% respectively, with DCR of 90.0% and
More news about: Mabwell
Oct 14, 2025, 09:00 ET TytoCare's AI Respiratory Suite Recognized on TIME's 2025 Best Inventions List
major abnormal lung sounds. The company recently completed its AI-powered Lung Sound Suite with the FDA clearance of Tyto Insights™ for Rhonchi, Wheeze, and Crackle Detection. TytoCare's platform offers comprehensive, AI-driven analysis of the three most clinically significant abnormal lung sounds directly
More news about: TytoCare
Oct 14, 2025, 09:00 ET Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025
National Cancer Center Hospital East (NCCHE) Japan, further validated the predictive power of Lunit SCOPE IO for ICI treatment response in non-small cell lung cancer (NSCLC) patients. In this multicenter prospective study, tumors classified as inflamed showed significantly better responses and longer survival
More news about: Lunit
Oct 14, 2025, 08:10 ET Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer
prostate, pancreatic, lung, and brain cancer. Candel has been granted multiple FDA designations, including Regenerative Medicine Advanced Therapy Designation (RMAT) for the treatment of localized prostate cancer, Fast Track Designation for localized prostate cancer and non-small cell lung cancer, and dual
More news about: Trinity Capital Inc.
Oct 14, 2025, 08:00 ET Orsini Selected as Specialty Pharmacy Partner for Boehringer Ingelheim's JASCAYD® (nerandomilast)
IPF is a progressive lung disease characterized by the gradual thickening and scarring of lung tissue. This scarring hinders the lungs' ability to efficiently transfer oxygen into the bloodstream, resulting in
More news about: Orsini
Oct 14, 2025, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
positive lung cancer, a subset of NSCLC that impacts mostly young, non-smoking individuals," said Ryan Confer, President and Chief Executive Officer at Genprex. "These preclinical data further validate REQORSA as a potential treatment for many types of cancer, including another subset of lung cancer,
More news about: Genprex, Inc.
Oct 14, 2025, 01:30 ET Smokefree India Calls on COP11 to Deliver Urgent Youth Protections Against Tobacco
Delhi, said, "The damage inflicted by traditional tobacco begins early and lasts a lifetime. We witness its devastating consequences daily—oral cancers, lung diseases, and heart conditions—often in individuals who started using these products in their teens. With 1.35 million deaths annually, the science
More news about: Smokefree India
Oct 13, 2025, 16:27 ET EiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
today announced the presentation of data for its brain- and lung-permeable pan-EGFR inhibitor, ZE77-0273 is a reversible small-molecule drug candidate that demonstrates broad activity against resistance mutations in EGFR-mutant non-small cell lung cancer (NSCLC), a high selectivity index versus wild-type
More news about: Eilean Therapeutics
Oct 13, 2025, 14:34 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRA
in a Phase 3 IMPALA-2 pivotal clinical trial for the treatment of autoimmune pulmonary alveolar proteinosis ("aPAP"), a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Savara has consistently represented that, based on investments
More news about: Pomerantz LLP